company background image

CranewareAIM:CRW Stock Report

Last Price


Market Cap







23 Jan, 2022


Company Financials +
CRW fundamental analysis
Snowflake Score
Future Growth4/6
Past Performance1/6
Financial Health6/6

CRW Stock Overview

Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States.

Craneware Competitors

EMIS Group






Kainos Group



Blue Prism Group



Price History & Performance

Summary of all time highs, changes and price drops for Craneware
Historical stock prices
Current Share PriceUK£23.50
52 Week HighUK£28.30
52 Week LowUK£20.00
1 Month Change-2.89%
3 Month Change2.62%
1 Year Change0%
3 Year Change-7.48%
5 Year Change80.08%
Change since IPO1,560.78%

Recent News & Updates

Nov 17
A Look At The Intrinsic Value Of Craneware plc (LON:CRW)

A Look At The Intrinsic Value Of Craneware plc (LON:CRW)

In this article we are going to estimate the intrinsic value of Craneware plc ( LON:CRW ) by projecting its future cash...

Sep 16
Here's Why I Think Craneware (LON:CRW) Is An Interesting Stock

Here's Why I Think Craneware (LON:CRW) Is An Interesting Stock

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Shareholder Returns

CRWGB Healthcare ServicesGB Market

Return vs Industry: CRW exceeded the UK Healthcare Services industry which returned -10.9% over the past year.

Return vs Market: CRW underperformed the UK Market which returned 7.8% over the past year.

Price Volatility

Is CRW's price volatile compared to industry and market?
CRW volatility
CRW Average Weekly Movement3.4%
Healthcare Services Industry Average Movement6.3%
Market Average Movement5.0%
10% most volatile stocks in GB Market10.7%
10% least volatile stocks in GB Market2.5%

Stable Share Price: CRW is less volatile than 75% of UK stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: CRW's weekly volatility (3%) has been stable over the past year.

About the Company

1999370Keith Neilson

Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. The company provides solutions, such as Chargemaster Toolkit, an automated software-as-a-service (SaaS) chargemaster management solution for capturing optimal legitimate reimbursement for providers; Trisus Supply, a solution that utilizes data to identify data gaps between the systems; Physician Revenue Toolkit, a SaaS solution for managing physician group KPIs, charges, codes, RVUs, fee schedules, and related information; Reference Plus, a SaaS solution to perform chargemaster analysis; Pharmacy ChargeLink, a solution to enhance charge capture, pricing, and cost management; integration for chargemaster management, a software that automatically uploads chargemaster changes to the patient billing system for accurate billing; Trisus Pricing Analyzer, a SaaS solution that simplifies the price modelling process; and Online Reference Toolkit and supplies assistant solutions. It also offers InSight Medical Necessity, a SaaS solution that provides medical necessity validation for the United States payors and advance beneficiary notice creation; Trisus Claims Informatics, a software that automates claim and coding reviews; and InSight Audit, a web-based audit management application for healthcare organizations to manage government and commercial audits.

Craneware Fundamentals Summary

How do Craneware's earnings and revenue compare to its market cap?
CRW fundamental statistics
Market CapUS$1.13b
Earnings (TTM)US$12.91m
Revenue (TTM)US$75.58m


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CRW income statement (TTM)
Cost of RevenueUS$5.37m
Gross ProfitUS$70.21m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date


Earnings per share (EPS)0.36
Gross Margin92.89%
Net Profit Margin17.08%
Debt/Equity Ratio0%

How did CRW perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio


Is Craneware undervalued compared to its fair value and its price relative to the market?


Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: CRW (£23.5) is trading below our estimate of fair value (£29.53)

Significantly Below Fair Value: CRW is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: CRW is poor value based on its PE Ratio (87.7x) compared to the European Healthcare Services industry average (48.4x).

PE vs Market: CRW is poor value based on its PE Ratio (87.7x) compared to the UK market (18.9x).

Price to Earnings Growth Ratio

PEG Ratio: CRW is poor value based on its PEG Ratio (3.3x)

Price to Book Ratio

PB vs Industry: CRW's PB Ratio (4.3x) is in line with the GB Healthcare Services industry average.

Future Growth

How is Craneware forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CRW's forecast earnings growth (26.4% per year) is above the savings rate (0.9%).

Earnings vs Market: CRW's earnings (26.4% per year) are forecast to grow faster than the UK market (12.1% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CRW's revenue (17.3% per year) is forecast to grow faster than the UK market (4.8% per year).

High Growth Revenue: CRW's revenue (17.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CRW's Return on Equity is forecast to be low in 3 years time (9.5%).

Past Performance

How has Craneware performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CRW has a large one-off loss of $6.5M impacting its June 30 2021 financial results.

Growing Profit Margin: CRW's current net profit margins (17.1%) are lower than last year (23.5%).

Past Earnings Growth Analysis

Earnings Trend: CRW's earnings have grown by 5.9% per year over the past 5 years.

Accelerating Growth: CRW's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: CRW had negative earnings growth (-23.3%) over the past year, making it difficult to compare to the Healthcare Services industry average (26.7%).

Return on Equity

High ROE: CRW's Return on Equity (5%) is considered low.

Financial Health

How is Craneware's financial position?

Financial Position Analysis

Short Term Liabilities: CRW's short term assets ($255.1M) exceed its short term liabilities ($49.4M).

Long Term Liabilities: CRW's short term assets ($255.1M) exceed its long term liabilities ($1.9M).

Debt to Equity History and Analysis

Debt Level: CRW is debt free.

Reducing Debt: CRW has not had any debt for past 5 years.

Debt Coverage: CRW has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: CRW has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet


What is Craneware current dividend yield, its reliability and sustainability?


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: CRW's dividend (1.19%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (1.41%).

High Dividend: CRW's dividend (1.19%) is low compared to the top 25% of dividend payers in the UK market (4.08%).

Stability and Growth of Payments

Stable Dividend: CRW's dividends per share have been stable in the past 10 years.

Growing Dividend: CRW's dividend payments have increased over the past 10 years.

Current Payout to Shareholders

Dividend Coverage: At its current payout ratio (78.5%), CRW's payments are covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: CRW's dividends in 3 years are forecast to be well covered by earnings (49.3% payout ratio).

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Keith Neilson (52 yo)





Mr. Keith Neilson co-founded Craneware PLC in 1999 and has served as its Chief Executive Officer ever since. Keith’s direction has helped Craneware to win multiple prestigious awards in such areas as inter...

CEO Compensation Analysis

Compensation vs Market: Keith's total compensation ($USD465.54K) is below average for companies of similar size in the UK market ($USD1.08M).

Compensation vs Earnings: Keith's compensation has been consistent with company performance over the past year.

Leadership Team

Experienced Management: CRW's management team is seasoned and experienced (11 years average tenure).

Board Members

Experienced Board: CRW's board of directors are considered experienced (4.8 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 34.2%.

Top Shareholders

Company Information

Craneware plc's employee growth, exchange listings and data sources

Key Information

  • Name: Craneware plc
  • Ticker: CRW
  • Exchange: AIM
  • Founded: 1999
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Implied Market Cap: UK£834.874m
  • Shares outstanding: 35.53m
  • Website:

Number of Employees


  • Craneware plc
  • 1 Tanfield
  • Edinburgh
  • EH3 5DA
  • United Kingdom


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/23 18:48
End of Day Share Price2022/01/21 00:00
Annual Earnings2021/06/30

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.